> 24 hr, delayed complication of<unk> 
Mortality > 90%, usually within 1-3 weeks of onset
Donor lymphocytes mount response against recipient tissue
Risk factors (see also Blood products):
Cellular components (whole blood, pRBCs)
Less incidence in platelet products
Almost none in FFP
Recipient immunodeficiency
Non-leukocyte irradiated blood products
Donor HLA homozygosity with recipient heterozygosity
Non-HLA matched blood products
Blood products stored less than 11 days
Longer shelf time associated with less incidence
In review of ~350 cases, only 10 identified between 11-14 days
Cellular components (whole blood, pRBCs)
Less incidence in platelet products
Almost none in FFP
Recipient immunodeficiency
Non-leukocyte irradiated blood products
Donor HLA homozygosity with recipient heterozygosity
Non-HLA matched blood products
Blood products stored less than 11 days
Longer shelf time associated with less incidence
In review of ~350 cases, only 10 identified between 11-14 days
Less incidence in platelet products
Almost none in FFP
Longer shelf time associated with less incidence
In review of ~350 cases, only 10 identified between 11-14 days
Transfusion-associated graft-versus-host disease
Acute
Transfusion-related acute lung injury
Intravascular hemolytic tranfusion reaction
Transfusion-associated circulatory overload
Febrile nonhemolytic tranfusion reaction
Immune reconstitution inflammatory syndrome
Allergic tranfusion reaction